Pathway to radical longevity – Induced Tissue Regeneration explained

Attacking the core biology of aging.

Full regeneration and immortalized cells exists in humans two weeks after conception.

There is work to re-activate those capabilities with adult cells.

The video and screenshots below are from the the CEO of AgeX Dr Michael West and another with Michael West talking with Dr. Aubrey de Grey, V.P. New Technology Discovery.

AgeX Therapeutics is a biotechnology company formed in 2017 as a subsidiary of BioTime, Inc (NYSE MKT: BTX). Its mission is to apply technology related to cell immortality and pluripotency to human aging and age-related disease. The Company’s technology platform has three facets: Pluripotent stem cell-derived progenitor cell lines representing over 200 types of cells in the body (PureStem technology); HyStem matrices; and induced tissue regeneration (iTR) – the latter being an emerging technology directed at inducing the immortal regeneration of tissues in the body.

Through BioTime, AgeX has license to a large consolidated technology and patent estate including the technologies Dr. West invented at Geron and his subsequent companies. AgeX is leading off with cell-based regenerative therapeutics for significant unmet needs in age-related disease such as Type II diabetes (using its manufactured brown adipocyte product (AGEX-BAT1)), and ischemic disease (using its young vascular progenitor cell product (AGEX-VASC1)). In addition, it will also be advancing products based on an entirely new technology platform aimed at the central molecular processes of aging itself designated “induced Tissue Regeneration (iTR)” AgeX scientists believe that the combination of telomerase therapy and iTR may unlock the potential of immortal tissue regeneration in humans. Model organisms that display immortal tissue regeneration show no evidence of aging.

The combination of pluripotent stem cell and iTR technology may provide AgeX with a highly differentiated and valuable platform to address large markets associated with chronic degenerative age-related disease.

Induced Tissue Regeneration
Some naturally-occurring animals such as the Mexican salamander can profoundly regenerate damaged tissues. Humans also have this potential, but only in the first weeks of development. Using advanced molecular and artificial intelligence technologies, we have identified pathways we believe may provide means of unlocking this profound biology in human medicine. The pathways suggest that they may also be integral to the biology of aging and cancer as well. Patents relating to this emerging technology called induced Tissue Regeneration (iTR), have been filed and animal studies are currently underway. iTR was the subject of a recent conference presentation from AgeX CEO Dr. Michael West.

Biotime has a presentation of their work towards antiaging.

logo

Don’t miss the latest future news

Subscribe and get a FREE Ebook